06/02/2026
Research advances in targeted leukemia therapy! 🚨
Current leukemia immunotherapies can struggle to distinguish cancerous cells from healthy tissue, limiting treatment precision and increasing side effects.
Researchers Dr. Christoph Rader and Dr. Matthew G. Cyr from Scripps Research and The Wertheim UF Scripps Institute have developed human antibodies that selectively target Siglec-6, a receptor associated with chronic lymphocytic leukemia (CLL) and other diseases. The platform can be developed into multiple therapeutic formats, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates.
By focusing on a more specific disease marker, this approach may enable more selective targeting of leukemia cells while sparing healthy tissue. This University of Florida innovation supports the development of more precise immunotherapies for blood cancers.
🔗 License this tech today: https://ufinnovate.technologypublisher.com/techcase/MP26054